Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...
Management anticipates top line data from the EXPLORE-OSA trial in the near future and continues to focus on pre-NDA preparations for lorundrostat, with a scheduled meeting with the FDA in Q4 2025.
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...
This article provides ChatGPT prompts to improve team meetings. It emphasizes pre-meeting preparation like mental resets and body language adjustments. Prompts guide crafting strong opening and ...